| Wendy W Lane, MD | |
|
900 Kiely Blvd, Santa Clara, CA 95051-5329 | |
| (408) 236-6400 | |
| Not Available |
| Full Name | Wendy W Lane |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 29 Years |
| Location | 900 Kiely Blvd, Santa Clara, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497834527 | NPI | - | NPPES |
| 00A621030 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | A62103 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital-santa Clara | Santa clara, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
Silencing a gene called Nrl in mice prevents the loss of cells from degenerative diseases of the retina, according to a new study.
BioMed Central, the world's largest open access publisher with over 200 peer-reviewed journals has teamed up with Quertle LLC to add over 60,000 published articles into the latest version of their innovative online biomedical search tool.
The recent report by NHS Cancer Director Professor Mike Richards on the uptake in the NHS of new cancer drugs makes clear that many more people are getting access to effective cancer drugs evaluated by the National Institute for Clinical Excellence.
One of the major challenges in stem cell transplants is how to obtain sufficient numbers of these remarkably rare cells to put into patients. To help overcome this issue, research from the Centenary Institute, Royal Prince Alfred Hospital and the University of Sydney has found a way to increase the number of blood-forming stem cells when growing them outside of the body.
AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.
› Verified 9 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Silencing a gene called Nrl in mice prevents the loss of cells from degenerative diseases of the retina, according to a new study.
BioMed Central, the world's largest open access publisher with over 200 peer-reviewed journals has teamed up with Quertle LLC to add over 60,000 published articles into the latest version of their innovative online biomedical search tool.
The recent report by NHS Cancer Director Professor Mike Richards on the uptake in the NHS of new cancer drugs makes clear that many more people are getting access to effective cancer drugs evaluated by the National Institute for Clinical Excellence.
One of the major challenges in stem cell transplants is how to obtain sufficient numbers of these remarkably rare cells to put into patients. To help overcome this issue, research from the Centenary Institute, Royal Prince Alfred Hospital and the University of Sydney has found a way to increase the number of blood-forming stem cells when growing them outside of the body.
AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Wendy W Lane, MD 1800 Harrison St Fl 7, Oakland, CA 94612-3466 Ph: (510) 625-6262 | Wendy W Lane, MD 900 Kiely Blvd, Santa Clara, CA 95051-5329 Ph: (408) 236-6400 |
News Archive
Silencing a gene called Nrl in mice prevents the loss of cells from degenerative diseases of the retina, according to a new study.
BioMed Central, the world's largest open access publisher with over 200 peer-reviewed journals has teamed up with Quertle LLC to add over 60,000 published articles into the latest version of their innovative online biomedical search tool.
The recent report by NHS Cancer Director Professor Mike Richards on the uptake in the NHS of new cancer drugs makes clear that many more people are getting access to effective cancer drugs evaluated by the National Institute for Clinical Excellence.
One of the major challenges in stem cell transplants is how to obtain sufficient numbers of these remarkably rare cells to put into patients. To help overcome this issue, research from the Centenary Institute, Royal Prince Alfred Hospital and the University of Sydney has found a way to increase the number of blood-forming stem cells when growing them outside of the body.
AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.
› Verified 9 days ago
David Clarke, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 900 Kiely Blvd, Santa Clara, CA 95051 Phone: 408-236-6400 | |
Joseph S. Chou, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 900 Kiely Blvd, Santa Clara, CA 95051 Phone: 408-236-6400 | |
Farhana Ahmed, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 710 Lawrence Expy, Santa Clara, CA 95051 Phone: 408-851-7222 | |
Gurpreet K. Ahluwalia, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 900 Kiely Blvd, Santa Clara, CA 95051 Phone: 408-236-6400 | |
Smita V. Gavaskar, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 900 Kiely Blvd, Santa Clara, CA 95051 Phone: 408-236-6400 | |
Anna Park, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 700 Lawrence Expy, Hospital Medicine 3rd Floor, Santa Clara, CA 95051 Phone: 408-851-7679 | |
Farida T. Madraswala, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 900 Kiely Blvd, Santa Clara, CA 95051 Phone: 408-236-6400 |